FindTrial
Sign In

Oral Risperidone

DRUG9 trials

Sponsors

Dartmouth-Hitchcock Medical Center, University of California, Los Angeles, Janssen Cilag N.V./S.A., Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Janssen-Cilag G.m.b.H

Conditions

Alcohol AbusePsychotic DisordersSchizoaffective DisorderSchizophreniaSubstance Abuse

Phase 1

Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia
CompletedNCT02411526
Zogenix, Inc.Schizoaffective Disorder, Schizophrenia
Start: 2015-02-28End: 2015-09-30Updated: 2022-10-31

Phase 3

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform
CompletedNCT02431702
Janssen Scientific Affairs, LLCPsychotic Disorders, Schizophrenia
Start: 2015-07-08End: 2019-11-12Updated: 2025-04-29

Phase 4

Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
CompletedNCT00130923
Dartmouth-Hitchcock Medical CenterAlcohol Abuse, Psychotic Disorders, Schizophrenia +1
Start: 2005-09-30End: 2010-07-31Updated: 2019-05-09
Improving Work Outcome in People With Recent-onset Schizophrenia
CompletedNCT00203788
University of California, Los AngelesSchizophrenia
Start: 1999-05-31End: 2006-12-31Updated: 2013-07-30
Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia
CompletedNCT00330551
University of California, Los AngelesSchizophrenia
Start: 2006-03-31End: 2012-11-30Updated: 2023-03-01
A Follow-Up Study of Schizophrenic Participants Following Treatment Discontinuation After Remission From a First Psychotic Episode
CompletedNCT00378092
Janssen Cilag N.V./S.A.Schizophrenia
Start: 2006-04-30End: 2010-03-31Updated: 2014-05-08
Study to Measure Drug Satisfaction of Patients With Schizophrenia After Switching From Risperidone to Paliperidone
CompletedNCT00535132
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Schizophrenia
Start: 2007-10-31End: 2008-07-31Updated: 2014-05-09
A Positron-Emission-Tomography (PET) Study to Measure the Blockade of Dopamine Receptors (D2) in Specific Areas of the Brain in Relation to the Plasma Concentrations of Paliperidone Extended Release (ER) and Oral Risperidone in Schizophrenia Patients and Healthy Controls
TerminatedNCT00934635
Janssen-Cilag G.m.b.HSchizophrenia
Start: 2009-09-30End: 2009-12-31Updated: 2014-02-11
28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years
TerminatedNCT00946985
Ortho-McNeil Janssen Scientific Affairs, LLCSchizophrenia
Start: 2009-06-30End: 2010-03-31Updated: 2012-09-10

Related Papers

Earlier Use of Long-Acting Injectable Paliperidone Palmitate Versus Oral Antipsychotics in Patients With Schizophrenia
The Journal of Clinical Psychiatry2023-09-212 citations
Effect of treatment with paliperidone palmitate versus oral antipsychotics on frontal lobe intracortical myelin volume in participants with recent-onset schizophrenia: Magnetic resonance imaging results from the DREaM study.
2023-03-312 citations
Real-world calibration and transportability of the Disease Recovery Evaluation and Modification (DREaM) randomized clinical trial in adult Medicaid beneficiaries with recent-onset schizophrenia
Journal of Managed Care & Specialty Pharmacy2023-01-241 citations
Dispersion of cognitive performance test scores on the MATRICS Consensus Cognitive Battery: A different perspective.
2022-09-051 citations
Evaluation of major treatment failure in patients with recent-onset schizophrenia or schizophreniform disorder: A post hoc analysis from the Disease Recovery Evaluation and Modification (DREaM) study
Schizophrenia Research2022-08-051 citations
The Disease Recovery Evaluation and Modification (DREaM) study: Effectiveness of paliperidone palmitate versus oral antipsychotics in patients with recent-onset schizophrenia or schizophreniform disorder
Schizophrenia Research2022-03-0213 citations
SU78. Intracortical Myelination Within the Frontal Lobe as a Potential Biomarker for Therapeutic Effectiveness in Antipsychotics Using MRI With Selective Myelin-Lipid Suppression at 1.5 and 3 T
Schizophrenia Bulletin2017-03-01
SA12. Baseline Demographics and Clinical Characteristics From a Prospective, Randomized, Open-Label Study of Paliperidone Palmitate Long-Acting Injection in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder
Schizophrenia Bulletin2017-03-01
Long-Acting Injectable vs Oral Risperidone for Schizophrenia and Co-Occurring Alcohol Use Disorder
The Journal of Clinical Psychiatry2015-08-1346 citations
Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study.
2012-04-0145 citations